Global Memantine Hydrochloride Extended-Release Capsule Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Memantine Hydrochloride Extended-Release Capsule Market Research Report 2024
Memantine hydrochloride extended-release capsules are a medication used in the treatment of Alzheimer's disease. The active ingredient in these capsules is memantine hydrochloride, which is a type of medication known as an N-methyl-D-aspartate (NMDA) receptor antagonist. Alzheimer's disease is a progressive neurodegenerative disorder that affects memory, thinking, and behavior. It is characterized by the accumulation of a protein called beta-amyloid in the brain, leading to the death of nerve cells and the disruption of normal brain function.
According to MRAResearch’s new survey, global Memantine Hydrochloride Extended-Release Capsule market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Memantine Hydrochloride Extended-Release Capsule market research.
Key companies engaged in the Memantine Hydrochloride Extended-Release Capsule industry include Lundbeck, Allergan, Novartis, Lupin Ltd, Huahai Pharmaceutical, Daiichi Sankyo Company Limited, Rottendorf Pharma GmbH, Polygen Pharms and Macleods Pharms, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Memantine Hydrochloride Extended-Release Capsule were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Memantine Hydrochloride Extended-Release Capsule market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Memantine Hydrochloride Extended-Release Capsule market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Lundbeck
Allergan
Novartis
Lupin Ltd
Huahai Pharmaceutical
Daiichi Sankyo Company Limited
Rottendorf Pharma GmbH
Polygen Pharms
Macleods Pharms
Amneal Pharms
Apeloa Pharmaceutical
HUMANWELL GROUP
Eisai Co
Ono Pharmaceutical
Slate Run
Easton Bio Pharmaceuticals
Segment by Type
7mg
14mg
21mg
28mg
Others
Home
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Memantine Hydrochloride Extended-Release Capsule report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Memantine Hydrochloride Extended-Release Capsule market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Memantine Hydrochloride Extended-Release Capsule market research.
Key companies engaged in the Memantine Hydrochloride Extended-Release Capsule industry include Lundbeck, Allergan, Novartis, Lupin Ltd, Huahai Pharmaceutical, Daiichi Sankyo Company Limited, Rottendorf Pharma GmbH, Polygen Pharms and Macleods Pharms, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Memantine Hydrochloride Extended-Release Capsule were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Memantine Hydrochloride Extended-Release Capsule market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Memantine Hydrochloride Extended-Release Capsule market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Lundbeck
Allergan
Novartis
Lupin Ltd
Huahai Pharmaceutical
Daiichi Sankyo Company Limited
Rottendorf Pharma GmbH
Polygen Pharms
Macleods Pharms
Amneal Pharms
Apeloa Pharmaceutical
HUMANWELL GROUP
Eisai Co
Ono Pharmaceutical
Slate Run
Easton Bio Pharmaceuticals
Segment by Type
7mg
14mg
21mg
28mg
Others
Segment by Application
Home
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Memantine Hydrochloride Extended-Release Capsule report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source